TetraLogic Provides Update on Ovarian Cancer Study

TetraLogic Pharmaceuticals Corporation TLOG today announced that it intends to proceed with the expansion phase of its study in patients with ovarian cancer. The study is being conducted in patients who have failed up to three rounds of prior chemotherapy. In the study birinapant has been dosed twice weekly, 3 weeks out of 4, or 4 weeks out of 4, in combination with Amgen's TRAIL receptor 2 agonist antibody, conatumumab, dosed every 2 weeks. Patients are scanned for disease status after every 8 weeks (2 cycles). To date eighteen patients have been dosed in the Phase 1b portion of the study. Results thus far suggest a pharmacodynamic interaction between the two drugs, manifested as the appearance of adverse events at lower than anticipated doses. In addition, one patient showed a partial response and two patients have maintained stable disease, one through four cycles of treatment, and one through two. Three additional patients are on study awaiting scans. Following a review of the data with the investigators, the recommendation is to continue the study, but to reduce the dose of birinapant and to limit dosing to 3 weeks out of 4. TetraLogic intends to continue the study until approximately thirty patients have been enrolled.